ZTSZoetis Inc.

$52B

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.3B+8.5% YoY

Gross Profit

$889M66.0% margin

Operating Income

$465M34.5% margin

Net Income

$298M22.1% margin

EPS (Diluted)

$0.61

QoQ Revenue Growth

+6.1%

Cash Flow

Operating Cash Flow

$439M

Free Cash Flow

$391M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$9.3B

Total Liabilities

$7.3B

Stockholders' Equity

$2.0B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.2B	+8.5%
Gross Profit	$889M	$812M	+9.5%
Operating Income	$465M	$377M	+23.3%
Net Income	$298M	$239M	+24.7%

Revenue Segments

Dogs and Cats

$546M41%

Cattle

$424M32%

Swine

$147M11%

Poultry

$119M9%

Fish

$39M3%

Horses

$34M3%

Sheep and Other

$25M2%

ZTS Q3 2017 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena